Parabilis Medicines has successfully completed a $670 million initial public offering, setting a new record in the biotechnology sector. This IPO reflects growing investor confidence in biotech companies and their potential for significant returns, indicating a robust trend in the market for such offerings.
INTELLIGENCE
Social Pulse
AI estimate · not scraped